Influence of Metabolic Risk Factors on the Risk of Bacterial Infections in Hepatitis B-Related Cirrhosis: A 10-Year Cohort Study.
bacterial infections
body mass index
diabetes
high-density lipoproteins
liver cirrhosis
triglycerides
Journal
Frontiers in medicine
ISSN: 2296-858X
Titre abrégé: Front Med (Lausanne)
Pays: Switzerland
ID NLM: 101648047
Informations de publication
Date de publication:
2022
2022
Historique:
received:
01
01
2022
accepted:
21
02
2022
entrez:
2
5
2022
pubmed:
3
5
2022
medline:
3
5
2022
Statut:
epublish
Résumé
The effect of metabolic factors on the risk of bacterial infections (BIs) in patients with hepatitis B virus (HBV)-related cirrhosis has not been demonstrated. This study aimed to explore specific metabolic factors associated with the BIs in these patients. A population-based cohort of 471 patients with HBV-related cirrhosis was retrospectively enrolled between 2009 and 2019. The primary end point was the incidence of BIs during hospitalization, which were compared according to the metabolism-related indicators, namely, presence of diabetes, level of high-density lipoprotein cholesterol (HDLC) and triglyceride, and body mass index (BMI). The propensity score matching (PSM) was adopted to eliminate baseline discrepancies. Compared with the non-diabetic group, the incidences of BIs were higher in the diabetic group before and after PSM ( In patients with HBV-related cirrhosis, the presence of diabetes and low level of HDLC were risk factors of BIs, showing a synergistic effect.
Identifiants
pubmed: 35492332
doi: 10.3389/fmed.2022.847091
pmc: PMC9046983
doi:
Types de publication
Journal Article
Langues
eng
Pagination
847091Informations de copyright
Copyright © 2022 Yang, Tong, Pi, Yu and Lv.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Hepatol. 2014 Jun;60(6):1310-24
pubmed: 24530646
J Hepatol. 2018 Aug;69(2):406-460
pubmed: 29653741
J Leukoc Biol. 2018 Sep;104(3):525-534
pubmed: 30066958
Liver Int. 2016 Jul;36(7):936-48
pubmed: 26972930
Nature. 2006 Dec 14;444(7121):881-7
pubmed: 17167477
J Hepatol. 2021 Jul;75 Suppl 1:S135-S146
pubmed: 34039484
Gastroenterology. 2019 Apr;156(5):1368-1380.e10
pubmed: 30552895
Liver Int. 2017 Apr;37(4):542-551
pubmed: 27740738
Hepatology. 2018 Aug;68(2):763-772
pubmed: 29356032
Hepatology. 2015 Jul;62(1):232-42
pubmed: 25800029
J Hepatol. 2012;56 Suppl 1:S1-12
pubmed: 22300459
Crit Care. 2020 Apr 7;24(1):134
pubmed: 32264946
Hepatology. 2018 Oct;68(4):1308-1318
pubmed: 29734463
Am J Gastroenterol. 2008 Jan;103(1):248
pubmed: 18184135
J Hepatol. 2020 Jul;73(1):113-120
pubmed: 32061870
Hepatology. 2014 Jul;60(1):250-6
pubmed: 24677131
Clin Microbiol Infect. 2018 May;24(5):546.e1-546.e8
pubmed: 28818628
Lancet Infect Dis. 2006 Jul;6(7):438-46
pubmed: 16790384
J Clin Invest. 2017 Jan 3;127(1):1-4
pubmed: 28045402
Endocr Rev. 2019 Oct 1;40(5):1367-1393
pubmed: 31098621
N Engl J Med. 2021 Jun 17;384(24):2317-2330
pubmed: 34133861
Biochim Biophys Acta. 2016 Jul;1861(7):630-8
pubmed: 27106140
Nat Rev Gastroenterol Hepatol. 2021 Apr;18(4):223-238
pubmed: 33349658
BMJ. 2020 Oct 12;371:m3109
pubmed: 33046451
Aliment Pharmacol Ther. 2014 Apr;39(8):883-93
pubmed: 24612251
Front Immunol. 2020 Jul 22;11:1582
pubmed: 32793223
J Infect Dis. 2021 Jul 15;224(2):294-302
pubmed: 33249474
Hepatology. 2014 Sep;60(3):823-31
pubmed: 24841704